ResearcherHarvard UniversityNo recent work listed
Gyulnara G. Kasumova
Matched on OpenAlex author ID A5024804731. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2016: 1 paper · 2017: 4 papers · 2018: 4 papers
Papers 9
- International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. First author DOI 10.1001/jamasurg.2018.3617↗
- Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. First author DOI 10.1007/s11605-017-3541-8↗
- Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. First author DOI 10.1016/j.hpb.2017.12.004↗
- The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-016-5676-3↗
- Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Co-author DOI 10.1002/cncr.30856↗
- Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Co-author DOI 10.1016/j.surg.2016.08.040↗
- Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.032↗
- Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Co-author DOI 10.1016/j.surg.2017.03.009↗
- Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.016923↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jennifer F. Tseng · 9 shared papers, 2016–2018 · strength 0.75
- Paper The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. DOI 10.1245/s10434-016-5676-3↗
- Paper Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. DOI 10.1200/jop.2016.016923↗
- Paper Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. DOI 10.1007/s11605-017-3541-8↗
- Susanna W.L. de Geus · 7 shared papers, 2017–2018 · strength 0.52
- Paper Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. DOI 10.1007/s11605-017-3541-8↗
- Paper Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic … DOI 10.1016/j.hpb.2017.12.004↗
- Paper Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matche… DOI 10.1016/j.surg.2016.08.040↗
- Mariam F. Eskander · 5 shared papers, 2017–2018 · strength 0.37
- Paper Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. DOI 10.1007/s11605-017-3541-8↗
- Paper Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matche… DOI 10.1016/j.surg.2016.08.040↗
- Paper Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. DOI 10.1016/j.surg.2016.09.032↗
- Mark P. Callery · 4 shared papers, 2017–2018 · strength 0.31
- Paper Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. DOI 10.1007/s11605-017-3541-8↗
- Paper Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic … DOI 10.1016/j.hpb.2017.12.004↗
- Paper Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matche… DOI 10.1016/j.surg.2016.08.040↗
- Tara Sotsky Kent · 4 shared papers, 2017–2018 · strength 0.29
- Paper Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. DOI 10.1007/s11605-017-3541-8↗
- Paper Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic … DOI 10.1016/j.hpb.2017.12.004↗
- Paper Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. DOI 10.1002/cncr.30856↗
- Rebecca Anne Miksad · 2 shared papers, 2016–2017 · strength 0.17
- Paper Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. DOI 10.1200/jop.2016.016923↗
- Paper Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. DOI 10.1016/j.surg.2017.03.009↗
- Arthur James Moser · 2 shared papers, 2018 · strength 0.16
- Alexander L. Vahrmeijer · 2 shared papers, 2018 · strength 0.16
- Anand Mahadevan · 2 shared papers, 2017 · strength 0.14
- William Charles Conway · 1 shared paper, 2018 · strength 0.14
- Teviah Erik Sachs · 1 shared paper, 2018 · strength 0.08
- Lindsay A. Bliss · 1 shared paper, 2017 · strength 0.08
- Joseph Douglas Mancias · 1 shared paper, 2017 · strength 0.07
- Matteo De Pastena · 1 shared paper, 2018 · strength 0.06
- Giuseppe Malleo · 1 shared paper, 2018 · strength 0.06
- Stijn R. van Roessel · 1 shared paper, 2018 · strength 0.06
- Francesco Giovinazzo · 1 shared paper, 2018 · strength 0.06
- Sanne Lof · 1 shared paper, 2018 · strength 0.06
- Laura Maggino · 1 shared paper, 2018 · strength 0.06
- Jacob L. van Dam · 1 shared paper, 2018 · strength 0.06
- Joanne Verheij · 1 shared paper, 2018 · strength 0.06
- Bas Groot Koerkamp · 1 shared paper, 2018 · strength 0.06
- Marc G. Besselink · 1 shared paper, 2018 · strength 0.06
- Claudio Bassi · 1 shared paper, 2018 · strength 0.06
- Casper H.J. van Eijck · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.